

- P-AKT-S473 expression in Figure 3C in *Genes Cancer 2014* and lanes 1–4 of DEPTOR expression in Figure 3C of *Cancer Res. 2016* with resizing.

- Lanes 7–9 of p70S6K1 expression in Figure 1A of *Genes Cancer 2014* and DEPTOR expression in Figure 4C of *Cancer Res. 2016*.

- STAT3 associated kinase activity in Figure 4A and lanes 1–4 of p110 mu associated kinase activity in Figure 5B of *Oncogene 2004*.

- Lanes 7–8 of ACTIN expression in Figure 1A and lanes 7–8 of ACTIN expression in Figure 1C of *PLoS One 2014*.

- Lanes 3–4 of P-MNK and T-MNK expression in Figure 1C of *PloS One 2014* and lanes 1–2 of FKHD-P and FKHD-T expression (top panels) in Figure 1B of *Mol Cancer Ther. 2005*.

- Lanes 4–8 of P-AKT (S473) and actin expression in Figure 2A of *Mol Cancer Ther. 2011* and AKT and S6K expression in Figure 1F of *PloS One 2017* with a 180 degree rotation of the P-AKT/AKT panels.

- Lanes 1–2 of T-HSP27 expression and lanes 4–5 of GAPDH expression in Figure 2B of *Oncogene 2013*.

- Lanes 1–3 of p-erk and lanes 2–4 of t-erk expression in Figure 3B and lanes 1–3 of erk(T202/Y204) and erk expression in Figure 4A of *J Biol Chem. 2012*.

- α -tubulin expression in Figure 4D and 4E of *Genes Cancer 2014*.

- C-myc expression in Figure 1B and lanes 1–4 of T-p70 expression in Figure 1E of *Oncogene 2016*.

- T-4E-BP1 (α , β and γ phosphorylated forms) expression (middle panel) and lanes 1–4 of T-4E-BP (α , β and γ phosphorylated forms) expression (right panel) of Supplemental Figure 2A of *Oncogene 2016*.

- T-S6 expression and C-myc expression in Figure 1F of *Oncogene 2016*.

- Lanes 2–5 of MNK-P and MNK-T expression (left panel) in Figure 3A and ERK-T and Hsp-27-T expression in Figure 4A of *Oncogene 2016*.

- MNK1, MNK2 and GAPDH expression in Figure 3E of *Oncogene 2016* and MNK1, MNK2 and GAPDH expression in Figure 3A of *PloS One 2014*.

- ire-1-total expression (right panel) in Figure 5B of *Mol Cancer Res. 2016* and mTor expression in Figure 8A of *Genes Cancer 2014* with resizing.

- The right panel of ACTIN expression in Figure 2A and the right panel of ACTIN expression in Figure 2g of *Mol Cancer Ther. 2019*.

- Lanes 1–6 of DEPTOR and mTOR expression in Figure 1A of *Genes*

Cancer 2014 and DEPTOR and mTor expression in Figure 6A of *Mol Cancer Ther. 2019*.

- IRS-1 expression in lanes 4–5 and lanes 8–9 in Figure 6B of *Mol Cancer Ther. 2005*.

- AKT expression (bottom panel) in Figure 1A and lanes 7–9 of IRS-1 expression in Figure 6B of *Mol Cancer Ther. 2005*.

- Lanes 4–6 of IGF-R expression and lanes 4–6 of FLAG expression in Figure 5B of *Mol Cancer Ther. 2005* with a 180-degree rotation.

- Lanes 2–3 of AKT-T expression (4th panel) in and lanes 1–2 of AKT-T expression (6th panel) in Figure 1C of *Mol Cancer Ther. 2005*.

- Lanes 1–2 of AKT-P expression (top panel) and lanes 1–2 of AKT-P expression (5th panel) in Figure 1E of *Mol Cancer Ther. 2005*.

- Lanes 1–3 and lanes 5–7 of FKH-T expression in Figure 3C of *Blood 2003*.

- Lane 1 of p70 expression and Ser411 expression in Figure 4B and lane 4 of Ser411 expression and lanes 1–2 of Ser411 expression in Figure 4c of *Blood 2003*.

- Lanes 1 and 3 of ERK-P expression and lanes 2 and 4 of ERK-T expression in Figure 2C of *Blood 2003*.

Based on these findings of research misconduct, which the Respondent did not appeal, the Department has imposed the following corrective actions:

- (1) Prohibition on conducting VA research for at least 2 years;

- (2) Notification to the relevant journals of the research misconduct findings.

Signing Authority

Denis McDonough, Secretary of Veterans Affairs, signed and approved this document on November 12, 2024, and authorized the undersigned to sign and submit the document to the Office of the Federal Register for publication electronically as an official document of the Department of Veterans Affairs.

Jeffrey M. Martin,

Assistant Director, Office of Regulation Policy & Management, Office of General Counsel, Department of Veterans Affairs.

[FR Doc. 2024-26756 Filed 11-15-24; 8:45 am]

BILLING CODE 8320-01-P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900-0012]

Agency Information Collection Activity Under OMB Review: Application for Cash Surrender or Policy Loan and Application for Cash Surrender (DocuSign)

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995, this notice announces that the Veterans Benefits Administration, Department of Veterans Affairs, will submit the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden, and it includes the actual data collection instrument.

DATES: Comments and recommendations for the proposed information collection should be sent by December 18, 2024.

ADDRESSES: To submit comments and recommendations for the proposed information collection, please type the following link into your browser: www.reginfo.gov/public/do/PRAMain, select “Currently under Review—Open for Public Comments”, then search the list for the information collection by Title or “OMB Control No. 2900-0012.”

FOR FURTHER INFORMATION CONTACT: VA PRA information: Maribel Aponte, (202) 461-8900, vacopaperworkreductact@va.gov.

SUPPLEMENTARY INFORMATION:

Title: Application for Cash Surrender or Policy Loan (VA Form 29-1546). Application for Cash Surrender (VA Form 29-1546e—DocuSign).

OMB Control Number: 2900-0012—<https://www.reginfo.gov/public/do/PRASearch>.

Type of Review: Extension without change of a currently approved collection.

Abstract: The Application for Cash Surrender or Policy Loan solicits information needed from Veterans to apply for cash surrender value or policy loan on his/her insurance. The VA Form 29-1546e has been added to this collection. This is an electronic version of the 29-1546 but is for cash surrender only. This form was created so Veterans can apply for a cash surrender of their policy online. This will not affect the number of respondents but will make it

easier and reduce the time it takes for Veterans to receive the cash value of their policy. The information on this form is required by law, 38 U.S.C. 1906 and 1944, 38 CFR 6.115, 6.116, 6.117, 8.27, 6.100, 6.101 and 8.28.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register**

Notice with a 60-day comment period soliciting comments on this collection of information was published at 89 FR 73507, September 10, 2024.

Affected Public: Individuals or Households.

Estimated Annual Burden: 4,939 hours.

Estimated Average Burden per Respondent: 10 minutes.

Frequency of Response: Upon Request.

Estimated Number of Respondents: 29,636.

Authority: 44 U.S.C. 3501 *et seq.*

Maribel Aponte,

VA PRA Clearance Officer, Office of Enterprise and Integration, Data Governance Analytics, Department of Veterans Affairs.

[FR Doc. 2024-26799 Filed 11-15-24; 8:45 am]

BILLING CODE 8320-01-P